Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome.

Trial Profile

Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Cancer; Peutz-Jeghers syndrome
  • Focus Therapeutic Use
  • Acronyms EVAM; EVAMP
  • Most Recent Events

    • 21 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 10 Feb 2012 Official title amended as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Additional lead trial investigator (Heinz-Josef Klumpen) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top